brand logo

Am Fam Physician. 2022;106(4):461-462

Clinical Question

Is treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors effective in decreasing hospitalization for patients with heart failure, even those without diabetes mellitus?

Bottom Line

In patients with heart failure, even in those without diabetes, adding an SGLT-2 inhibitor to treatment will have a modest effect on decreasing the likelihood of hospitalization for heart failure. In a previous meta-analysis with fewer studies overall, mortality risk was not reduced, although cardiovascular mortality was slightly decreased. Several guideline development groups have added SGLT-2 inhibitors to their treatment algorithms. (Level of Evidence = 1a)

Synopsis

The researchers followed PRISMA guidelines for conducting and reporting the analysis. They searched four databases, including the Cochrane Library, as well as reference lists and other systematic reviews, and they polled experts. They identified eight randomized controlled trials, published in English, enrolling a total of 15,022 patients with heart failure who were followed up for at least six months. Most of the trials were at low risk of bias, and heterogeneity among study results was very low. Adding SGLT-2 inhibitor treatment to existing therapy reduces the risk of hospitalization over the first six months by approximately one-third (i.e., 41 to 78 fewer hospitalizations per 1,000 people treated). All-cause mortality was not affected by treatment, but cardiovascular mortality was decreased with treatment (i.e., 2 to 41 fewer deaths per 1,000 patients treated over one year). There was no difference in outcomes for patients with or without diabetes or preserved or reduced ejection fraction. The effect of treatment was greater in the first year and in patients with a poorer prognosis. The analysis did not attempt to differentiate effectiveness among the SGLT-2 inhibitor options.

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/Home/Loe?show=Sort.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Natasha J. Pyzocha, DO, contributing editor.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.